ATE352302T1 - Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze - Google Patents

Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze

Info

Publication number
ATE352302T1
ATE352302T1 AT02790172T AT02790172T ATE352302T1 AT E352302 T1 ATE352302 T1 AT E352302T1 AT 02790172 T AT02790172 T AT 02790172T AT 02790172 T AT02790172 T AT 02790172T AT E352302 T1 ATE352302 T1 AT E352302T1
Authority
AT
Austria
Prior art keywords
pyridylmethylaminomethyl
chromane
fluorophenyl
acceptable salts
physiologically acceptable
Prior art date
Application number
AT02790172T
Other languages
German (de)
English (en)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE352302T1 publication Critical patent/ATE352302T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02790172T 2001-07-26 2002-07-10 Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze ATE352302T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26

Publications (1)

Publication Number Publication Date
ATE352302T1 true ATE352302T1 (de) 2007-02-15

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02790172T ATE352302T1 (de) 2001-07-26 2002-07-10 Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze

Country Status (23)

Country Link
US (1) US7872030B2 (https=)
EP (1) EP1408964B1 (https=)
JP (1) JP2004538289A (https=)
KR (1) KR20040029325A (https=)
CN (1) CN1292749C (https=)
AR (1) AR037496A1 (https=)
AT (1) ATE352302T1 (https=)
AU (1) AU2002355170B2 (https=)
BR (1) BR0211358A (https=)
CA (1) CA2455621C (https=)
CY (1) CY1107616T1 (https=)
DE (1) DE60217870T2 (https=)
DK (1) DK1408964T3 (https=)
ES (1) ES2280602T3 (https=)
HU (1) HUP0402092A3 (https=)
MX (1) MXPA04000775A (https=)
MY (1) MY134059A (https=)
PE (1) PE20030277A1 (https=)
PL (1) PL208258B1 (https=)
PT (1) PT1408964E (https=)
RU (1) RU2297833C2 (https=)
SI (1) SI1408964T1 (https=)
WO (1) WO2003009835A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
PT2161038E (pt) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
EP3626823A1 (en) * 2009-09-11 2020-03-25 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
AU3929493A (en) 1992-03-11 1993-10-05 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
CN1155567C (zh) 1998-04-29 2004-06-30 惠氏公司 抑制精神的吲哚基衍生物
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
PL367291A1 (en) 2005-02-21
HUP0402092A2 (hu) 2005-02-28
RU2297833C2 (ru) 2007-04-27
AR037496A1 (es) 2004-11-17
AU2002355170B2 (en) 2007-06-07
DE60217870D1 (de) 2007-03-15
DE60217870T2 (de) 2007-11-15
CN1535150A (zh) 2004-10-06
ES2280602T3 (es) 2007-09-16
MY134059A (en) 2007-11-30
KR20040029325A (ko) 2004-04-06
SI1408964T1 (sl) 2007-06-30
PT1408964E (pt) 2007-05-31
CA2455621C (en) 2010-11-16
WO2003009835A3 (en) 2003-08-07
DK1408964T3 (da) 2007-05-21
WO2003009835A2 (en) 2003-02-06
CY1107616T1 (el) 2013-03-13
MXPA04000775A (es) 2004-04-20
US20040171645A1 (en) 2004-09-02
RU2004105844A (ru) 2005-05-10
PL208258B1 (pl) 2011-04-29
PE20030277A1 (es) 2003-03-25
CN1292749C (zh) 2007-01-03
BR0211358A (pt) 2004-09-21
US7872030B2 (en) 2011-01-18
EP1408964B1 (en) 2007-01-24
JP2004538289A (ja) 2004-12-24
HK1068793A1 (en) 2005-07-29
EP1408964A2 (en) 2004-04-21
HUP0402092A3 (en) 2010-06-28
CA2455621A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60229061D1 (de) Herstellung und verwendung von nanopartikel
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
ATE367381T1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
ATE299881T1 (de) 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
NO20033538L (no) Nytt suksinatsalt av O-desmetyl-venlafaxine
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE50212455D1 (de) Verwendung von Dimerdiolen
EP1499186A4 (en) USE OF HEME-OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
DE60230883D1 (de) Neue formulierungen und ihre verwendung
EE200400043A (et) Uudsed heterotsüklilised ühendid kui selektiivsedbakteriaalsed DHFR inhibiitorid ning nende kasutamine
ATE352302T1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
NO20035332D0 (no) Nye heterocykliske derivater og medisinsk anvendelse derav

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1408964

Country of ref document: EP